Streetbeat News

Products Services

ALZN

Alzamend Neuro has submitted an Investigational New Drug (IND) application for a Phase IIA clinical trial of its lithium therapeutics drug candidate AL001 in patients with major depressive disorder.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:30 am

VERV

Verve Therapeutics has received clearance from the FDA for its Investigational New Drug application for VERVE-101 in patients with heterozygous familial hypercholesterolemia. This has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:22 am

TOVX

Theriva Biologics presented new clinical data from a Phase 1 study evaluating VCN-01 in combination with Durvalumab at the European Society for Medical Oncology (ESMO) Congress. The results validate VCN-01's unique mechanism of action for devastating cancers with high unmet need.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:12 am

VKTX

Viking Therapeutics has completed enrollment in its Phase 2 VENTURE trial of VK2735, a dual GLP-1/GIP receptor agonist, in patients with obesity. This marks a significant milestone in the company's clinical development program.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:08 am

ONCY

Oncolytics Biotech has achieved success criteria for efficacy in the third-line colorectal cancer cohort of the Phase 1/2 GOBLET study.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:07 am

ACON

ATEC

Aclarion has signed a Letter of Intent (LOI) with ATEC to advance the commercialization of Nociscan. The partnership aims to bring the product to market more quickly.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:06 am

UNCY

Unicycive Therapeutics is planning to file a New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) using the 505(b)(2) regulatory pathway. This pathway allows Unicycive to reference the currently approved drug, Fosrenol.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:04 am

FSR

Fisker has reduced the US pricing on the Ocean Extreme Trim from $68,999 to $61,499 and also lowered the Canada pricing on the same model from $89,999 CAD to $79,799 CAD.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:04 am

V

Visa has announced the pilot launch of Visa AR Manager, a new tool designed to simplify commercial virtual card acceptance. The tool aims to streamline the process of accepting and processing virtual card payments for businesses.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:01 am

EGRX

Eagle Pharmaceuticals has been granted a unique J-Code and pass-through status for BARHEMSYS by the Centers for Medicare & Medicaid Services (CMS).

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 10:59 am